Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kevin J Harrington"'
Autor:
Kenji Hirotani, Martin Forster, Shuquan Chen, Christophe Le Tourneau, Jonathan Greenberg, Jose Ariza, Éva Remenár, Kevin J. Harrington
Publikováno v:
Journal of Clinical Oncology. 36:6045-6045
6045Background: P, a fully human monoclonal antibody can block HER3 activation. HER3 activation is a resistance mechanism to C, induced by the ligand heregulin (HRG). This randomized phase 2 study ...
Autor:
Luciano de Souza Viana, Tomoya Yokota, José Dinis, Manuel Chaves-Conde, Chaitali Singh Nangia, Jan B. Vermorken, J.G.M. Segalla, Robert I. Haddad, Ilya Romanov, Jean Bourhis, Jose Manuel Trigo Perez, Kevin J. Harrington, Irina A. Vasilevskaya, E. Ehrnrooth, Amanda Psyrri, Neil W. Gibson, Bushi Wang, Ezra E.W. Cohen, Makoto Tahara, Barbara Burtness
Publikováno v:
Journal of Clinical Oncology. 35:6001-6001
6001 Background: Locally advanced HNSCC is treated curatively, but recurrence is common. In HNSCC, EGFR is richly expressed and EGFR inhibition is validated treatment (tx); the ErbB family blocker afatinib (A) showed efficacy in recurrent/metastatic
Autor:
Kevin J. Harrington, Jonathan Greenberg, Kandance Cooper, Henrik Hannus, Sola Adeleke, Shuquan Chen, Jane S. Diamond, Martin Forster, Lorna Grove, Magnus T. Dillon
Publikováno v:
Journal of Clinical Oncology. 34:TPS6104-TPS6104
TPS6104Background: P is a fully human monoclonal antibody against human epidermal growth factor receptor 3. P blocks activation by the ligand, heregulin (HRG), inducing receptor internalization. Ev...
Autor:
Petra Holečková, Georgy M. Manikhas, Iman El-Hariry, Natalie Franklin, Sergio Santillana, Hisham Mehanna, Paul Wissel, Minish Mahendra Jain, Geza Horvai, Stéphane Temam, Thelma Netherway, Jean Bourhis, Nigel Biswas-Baldwin, Ida D'Onofrio, Yan Sun, Stefan Dietzsch, Pavol Dubinsky, Philippe Legenne, Kevin J. Harrington, Anil K. D'Cruz
Publikováno v:
ResearcherID
6005 Background: Epidermal growth factor receptor (EGFR) and ErbB2 are overexpressed in up to 90% and 40% of SCCHN, respectively. L, a tyrosine kinase inhibitor (TKI) of both EGFR and ErbB2, demonstrates tumor responses in SCCHN. Methods: Patients wi